Tissue biopsy monitoring of operational tolerance in liver allograft recipients

Current Opinion in Organ Transplantation

Volumn 18, Issue 3, 2013, Pages 345-353

  Demetris, Anthony J ^a   Isse, Kumiko ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Biopsy monitoring; C4d; Fibrosis; Operational tolerance

Indexed keywords

ANTIBODY MEDIATED REJECTION; AUTOIMMUNITY; BIOPSY TECHNIQUE; CROSS REACTION; DISEASE COURSE; GENE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IRON METABOLISM; LIVER FIBROSIS; LIVER GRAFT; LIVER GRAFT REJECTION; PATIENT MONITORING; REGULATORY T LYMPHOCYTE; REVIEW; UPREGULATION; ALLOTRANSPLANTATION; BIOPSY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LIVER; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; PHYSIOLOGY;

COMPLEMENT C4D; COMPLEMENT COMPONENT C4B; IMMUNOSUPPRESSIVE AGENT; PEPTIDE FRAGMENT;

BIOPSY; COMPLEMENT C4B; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; PEPTIDE FRAGMENTS; TRANSPLANTATION, HOMOLOGOUS;

MLCS; MLOWN;

EID: 84879958033     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283615d48     Document Type: Review

References (90)

1. Banff Working G. Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. Liver Transpl 2012; 18:1154-1170.
2. Banff Working G, Demetris AJ, Adeyi O, et al. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44:489-501.
3. Hubscher SG. What is the long-term outcome of the liver allograft? J Hepatol 2011; 55:702-717.
4. Demetris AJ, Lunz JG 3rd, Randhawa P, et al. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22:120-141.
5. Knechtle SJ, Kwun J. Unique aspects of rejection and tolerance in liver transplantation. Semin Liver Dis 2009; 29:91-101.
6. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007; 17:94-97.
7. Yoshitomi M, Koshiba T, Haga H, et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation 2009; 87:606-614.
8. Egawa H, Miyagawa-Hayashino A, Haga H, et al. Non-inflammatory centrilobular sinusoidal fibrosis in pediatric liver transplant recipients under tacrolimus withdrawal. Hepatol Res 2012; 42:895-903.
9. Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307:283-293.
10. Sanchez-Fueyo A. Identification of tolerant recipients following liver transplantation. Int Immunopharmacol 2010; 10:1501-1504.
11. Lerut J, Sanchez-Fueyo A. An appraisal of tolerance in liver transplantation. Am J Transplant 2006; 6:1774-1780.
12. Girnita A, Mazariegos GV, Castellaneta A, et al. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum Immunol 2010; 71:274-276.
13. Murphy MS, Harrison R, Davies P, et al. Risk factors for liver rejection: evidence to suggest enhanced allograft tolerance in infancy. Arch Dis Child 1996; 75:502-506.
14. Talisetti A, Hurwitz M, Sarwal M, et al. Analysis of clinical variables associated with tolerance in pediatric liver transplant recipients. Pediatr Transpl 2010; 14:976-979.
15. Abo T. Extrathymic pathways of T-cell differentiation and immunomodulation. Int Immunopharmacol 2001; 1:1261-1273.
16. Tisone G, Orlando G, Cardillo A, et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J Hepatol 2006; 44: 702-709.
17. Wong T, Nouri-Aria KT, Devlin J, et al. Tolerance and latent cellular rejection in long-term liver transplant recipients. Hepatology 1998; 28:443-449.
18. Bohne F, Martinez-Llordella M, Lozano JJ, et al. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Investig 2012; 122:368-382.
19. Zhao X, Li Y, Ohe H, et al. Intragraft Vdelta1 gamma delta T cells with a unique T-cell receptor are closely associated with pediatric semiallogeneic liver transplant tolerance. Transplantation 2013; 95:192-202.
20. Li Y, Zhao X, Cheng D, et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation 2008; 86:1837-1843.
21. Kamar N, Garrouste C, Haagsma EB, et al. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology 2011; 140:1481-1489.
22. Pischke S, Suneetha PV, Baechlein C, et al. Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl 2010; 16:74-82.
23. Pischke S, Wedemeyer H. Chronic hepatitis E in liver transplant recipients: a significant clinical problem? Minerva Gastroenterol Dietol 2010; 56:121-128.
24. Haagsma EB, Riezebos-Brilman A, van den Berg AP, et al. Treatment of chronic hepatitis E in liver transplant recipients with pegylated interferon alpha-2b. Liver Transpl 2010; 16:474-477.
25. Kamar N, Abravanel F, Selves J, et al. Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation 2010; 89:353-360.
26. Haagsma EB, Niesters HG, van den Berg AP, et al. Prevalence of hepatitis E virus infection in liver transplant recipients. Liver Transpl 2009; 15:1225-1228.
27. Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358:811-817.
28. Halac U, Beland K, Lapierre P, et al. Chronic hepatitis E infection in children with liver transplantation. Gut 2012; 61:597-603.
29. Aggarwal R, Jameel S. Hepatitis E. Hepatology 2011; 54:2218-2226.
30. Mendes F, Couto CA, Levy C. Recurrent and de novo autoimmune liver diseases. Clin Liver Dis 2011; 15:859-878.
31. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139:58-72.
32. Aguilera I, Sousa JM, Gavilan F, et al. Complement component 4d immunostaining in liver allografts of patients with de novo immune hepatitis. Liver Transpl 2011; 17:779-788.
33. Inui A, Sogo T, Komatsu H, et al. Antibodies against cytokeratin 8/18 in a patient with de novo autoimmune hepatitis after living-donor liver transplantation. Liver Transpl 2005; 11:504-507.
34. Huguet S, Vinh J, Johanet C, et al. Identification by proteomic tool of atypical antiliver/kidney microsome autoantibodies targets in de novo autoimmune hepatitis after liver transplantation. Ann N Y Acad Sci 2007; 1109:345-357.
35. Pappo O, Ramos H, Starzl TE, et al. Structural integrity and identification of causes of liver allograft dysfunction occurring more than 5 years after transplantation. Am J Surg Pathol 1995; 19:192-206.
36. Gane E, Portmann B, Saxena R, et al. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20:88-94.
37. Eguchi S, Takatsuki M, Hidaka M, et al. Lack of grafted liver rejuvenation in adult-to-pediatric liver transplantation. Dig Dis Sci 2011; 56:1542-1547.
38. Devarbhavi H, Abraham S, Kamath PS. Significance of nodular regenerative hyperplasia occurring de novo following liver transplantation. Liver Transpl 2007; 13:1552-1556.
39. Miyagawa-Hayashino A, Yoshizawa A, Uchida Y, et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transpl 2012; 18:1333-1342.
40. Yamada H, Kondou H, Kimura T, et al. Humoral immunity is involved in the development of pericentral fibrosis after pediatric live donor liver transplantation. Pediatr Transplant 2012; 16:858-865.
41. Ramos HC, Reyes J, Abu-Elmagd K, et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation 1995; 59:212-217.
42. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997; 63:243-249.
43. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001; 72:449-454.
44. Suciu-Foca N, Harris PE, Cortesini R. Intramolecular and intermolecular spreading during the course of organ allograft rejection. Immunol Rev 1998; 164:241-246.
45. Obata F, Yoshida K, Ikeda Y, et al. Clonality analysis of T cells mediating acute and chronic rejection in kidney allografts. Transpl Immunol 2004; 13:233-237.
46. Eghtesad B, Fung JJ, Demetris AJ, et al. Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl 2005; 11:1343-1352.
47. Eason JD, Cohen AJ, Nair S, et al. Tolerance: is it worth the risk? Transplantation 2005; 79:1157-1159.
48. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Clin Liver Dis 2011; 15:515-536.
49. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49:1017-1044.
50. Isse K, Lesniak A, Grama K, et al. Digital transplantation pathology: combining whole slide imaging, multiplex staining and automated image analysis. Am J Transpl 2012; 12:27-37.
51. Dar W, Agarwal A, Watkins C, et al. Donor-directed MHC class I antibody is preferentially cleared from sensitized recipients of combined liver/kidney transplants. Am J Transpl 2011; 11:841-847.
52. Demetris AJ, Murase N, Nakamura K, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. [Review]. Semin Liver Dis 1992; 12:51-59.
53. Bellamy CO, Herriot MM, Harrison DJ, Bathgate AJ. C4d immunopositivity is uncommon in ABO-compatible liver allografts, but correlates partially with lymphocytotoxic antibody status. Histopathology 2007; 50:739-749.
54. Bu X, Zheng Z, Yu Y, et al. Significance of C4d deposition in the diagnosis of rejection after liver transplantation. Transplant Proc 2006; 38:1418-1421.
55. Dankof A, Schmeding M, Morawietz L, et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005; 447:87-93.
56. Haga H, Egawa H, Fujimoto Y, et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12:457-464.
57. Jain A, Mohanka R, Orloff M, et al. Characterization of CD4, CD8, CD56 positive lymphocytes and C4d deposits to distinguish acute cellular rejection from recurrent hepatitis C in postliver transplant biopsies. Clin Transplant 2006; 20:624-633.
58. Krukemeyer MG, Moeller J, Morawietz L, et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78:65-70.
59. Sakashita H, Haga H, Ashihara E, et al. Significance of C4d staining in ABO-identical/compatible liver transplantation. Mod Pathol 2007; 20:676-684.
60. Sawada T, Shimizu A, Kubota K, et al. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005; 19:110-114.
61. Troxell ML, Higgins JP, Kambham N. Evaluation of C4d staining in liver and small intestine allografts. Arch Pathol Lab Med 2006; 130:1489-1496.
62. Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transpl 2011; 11:500-510.
63. Lunz J, Ruppert KM, Cajaiba MM, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transpl 2012; 12:171-182.
64. Kozlowski T, Rubinas T, Nickeleit V, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011; 17:357-368.
65. Martelius T, Halme L, Arola J, et al. Vascular deposition of complement C4d is increased in liver allografts with chronic rejection. Transpl Immunol 2009; 21:244-246.
66. Ohtani O, Ohtani Y. Lymph circulation in the liver. Anat Rec (Hoboken) 2008; 291:643-652.
67. Demetris AJ. Central venulitis in liver allografts: considerations of differential diagnosis. Hepatology 2001; 33:1329-1330.
68. Gugenheim J, Rouger P, Gane P, et al. Expression of blood group antigens including HLA markers on human liver allografts. Transplant Proc 1987; 19:223-225.
69. Rouger P, Gugenheim J, Gane P, et al. Distribution of the MHC antigens after liver transplantation: relationship with biochemical and histological parameters. Clin Exp Immunol 1990; 80:404-408.
70. Rouger P, Poupon R, Gane P, et al. Expression of blood group antigens including HLA markers in human adult liver. Tissue Antigens 1986; 27:78-86.
71. Demetris AJ, Lasky S, Thiel DHV, et al. Induction of DR/IA antigens in human liver allografts: an immunocytochemical and clinicopathologic analysis of twenty failed grafts. Transplantation 1985; 40:504-509.
72. Lautenschlager I, Taskinen E, Inkinen K, et al. Distribution of the major histocompatibility complex antigens on different cellular components of human liver. Cell Immunol 1984; 85:191-200.
73. Steinhoff G, Wonigeit K, Pichlmayr R. Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Transplantation 1988; 45:394-401.
74. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of HLA-A, B, C antigens in normal human organs. Transplantation 1984; 38:287-292.
75. Daar AS, Fuggle SV, Fabre JW, et al. The detailed distribution of MHC Class II antigens in normal human organs. Transplantation 1984; 38:293-298.
76. So SK, Platt JL, Ascher NL, Snover DC. Increased expression of class I major histocompatibility complex antigens on hepatocytes in rejecting human liver allografts. Transplantation 1987; 43:79-85.
77. Gouw AS, Houthoff HJ, Huitema S, et al. Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. Transplantation 1987; 43:291-296.
78. Vinas O, Bataller R, Sancho-Bru P, et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003; 38:919-929.
79. Steinhoff G. Major histocompatibility complex antigens in human liver transplants. J Hepatol 1990; 11:9-15.
80. Prickett TCR, McKenzie JL, Hart DNJ. Characterization of interstitial dendritic cells in human liver. Transplantation 1988; 46:754-761.
81. Hoshino J, Kaneku H, Everly MJ, et al. Using donor-specific antibodies to monitor the need for immunosuppression. Transplantation 2012; 93:1173-1178.
82. Augustine JJ, Woodside KJ, Padiyar A, et al. Independent of nephrectomy, weaning immunosuppression leads to late sensitization after kidney transplant failure. Transplantation 2012; 94:738-743.
83. Terada T, Nakanuma Y, Obata H. HLA-DR expression onthe microvasculature of portal tracts in idiopathic portal hypertension. Immunohistochemical characteristics and relation to portal phlebosclerosis. Arch Pathol Lab Med 1991; 115:993-997.
84. Terada T, Nakanuma Y, Hoso M, Obata H. Expression of HLA-DR antigen on hepatic vascular endothelial cells in idiopathic portal hypertension. Clin Exp Immunol 1991; 84:303-307.
85. Gelson W, Hoare M, Vowler S, et al. Features of immune senescence in liver transplant recipients with established grafts. Liver Transpl 2010; 16:577-587.
86. Sanchez-Fueyo A, Strom TB. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011; 140:51-64.
87. Orlando G, Manzia T, Baiocchi L, et al. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant patients: the updated follow up at 78 months. Transpl Immunol 2008; 20:43-47.
88. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008; 118:2845-2857.
89. Dinu I, Potter JD, Mueller T, et al. Gene-set analysis and reduction. Brief Bioinform 2009; 10:24-34.
90. Bunnag S, Einecke G, Reeve J, et al. Molecular correlates of renal function in kidney transplant biopsies. J Am Soc Nephrol 2009; 20:1149-1160.